Vincent Macciocchi
Analyst · Seaport Global
Thank you, Eric. I think if you think about our business -- and maybe I'll start kind of where you finished in terms of some of our greatest strengths. I think our greater strengths are obviously the breadth and depth of the pantry coupled with our technical capabilities and providing solutions backed by science. I think you also marry that with the global consumer trends when you think about the focus on the microbiome, focus on plant-based foods, sustainability and good for you, and you think about clean label moving to clear label.
Our portfolio is really well positioned when you think about our flavors business and the focus on natural and our continued growth in the mature market and as we expand our footprint into the emerging markets.
Specialty ingredients, obviously, we have a dominant share as a key protein -- plant-based protein provider. And we're providing soy, pea and wheat from a plant-based protein perspective and really capitalizing on that global consumer trend.
If you look at our Health and Wellness business, we have a fantastic portfolio, really focused on probiotics and postbiotics as well as fiber as well as vitamins as well as specialty oil, so a really complete portfolio across Health and Wellness.
And then obviously in Animal Nutrition, we completed the acquisition of Neovia in 2019. Obviously, we've over-delivered against the synergy targets, but it's a global, robust business. It's really focused on, obviously, complete feed additives and ingredients, aquaculture, pet. So really moving that portfolio to realize synergies, grow organically and capitalize on our global footprint.
So where is our opportunity? There's certainly opportunity to further expand in the flavors business into emerging markets. We're always looking at technology in our portfolio and geography, in the plant-based business and specialty ingredients. It's really making sure we're providing outside of the Americas and looking to enhance our footprint there.
In Health and Wellness, it's really capitalizing on the microbiome and expanding our capability. Juan mentioned in his remarks that we're expanding our facility in Valencia, Spain. That will give us significant capacity increase to capitalize on our growing demand.
And then on animal, I think our story is really one where we finish the integration, we grow organically, we margin up that portfolio, and we continue to combine all pieces of our portfolio and provide solutions backed by science.